Promontory Therapeutics, Inc.

Big backing for venture capital-funded private biopharmaceutical companies has not wavered as 2021 draws to a close despite a recent slowdown in large initial public offerings by drug developers in th

Industry leaders and experts envisage positive change in the biopharma sector over the coming year, fueled by advances in science and data processing. The application of artificial intelligence will i

"COVID-19 is a great reminder and a testament that biopharma's core mission is to meet patient and society's needs." These words of Lihua Yu , president and chief data science officer of Eisai Co.,

"The coming year will be remembered for the epic alteration to our society." These words from Pam Contag , CEO and co-founder of BioEclipse Therapeutics, Inc. , encapsulate the enormity of COVID-19'